Charasteristics of COVID-19 Patients Treated At Santa Elisabeth Medan Hospital 2020

Authors

  • Nency Triputri FK USU
  • Noni Novisari Soeroso Department of Pulmonology, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, Indonesia

DOI:

https://doi.org/10.32734/sumej.v4i1.5958

Keywords:

Characteristic, COVID-19, Positive, Confirmed

Abstract

Corona Virus Disease (COVID-19) is a disease caused by a new type of coronavirus (SARS-CoV-2). This virus was first discovered in Wuhan, China for the first time and has infected 90,308 people as of March 2, 2020. Infection is transmitted by large droplets or droplets within 1 - 2 m, which are generated during coughing and sneezing by symptomatic patients and people without symptoms. This infection is acquired by inhaling these droplets or touching a contaminated surface and then touching the nose, mouth and eyes.  To see the characteristics of COVID-19 patients who are treated at the Santa Elisabeth Hospital Medan in 2020.  Type of research is a descriptive study with a cross-sectional study design with a retrospective approach using total sampling technique. This type of research data is secondary data obtained from the medical record data of positive COVID-19 patients confirmed to be hospitalized in several Medan city hospitals in 2020.Of the 230 study samples, 147 confirmed positive COVID-19 patients were found, dominated by the age range 46-55 years. The sex most common is male. The most common clinical symptoms are respiratory disorders such as coughing, shortness of breath and fever.The number of confirmed positive patients at the hospital. Santa Elisabeth in March to October 2020 is 147 people (51.1%).

Downloads

Download data is not yet available.

References

infection when novel coronavirus (2019-nCoV) infection is suspected. interim guidance. Available on: https://www.who.int/publications-detail/clinical-management-ofsevere-acute-respiratory-infection-when-novel-coronavirus(ncov)-infection-is-suspected.

Kementerian Kesehatan Republik Indonesia.2020 Pedoman Pencegahan dan Pengendalian Coronavirus Disease (Covid-19) revisi ke-4

Kementerian Kesehatan Republik Indonesia.2020 Pedoman Kesiapsiagaan Menghadapi Coronavirus Disease (COVID-19) Revisi ke-3

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med; published online March 18. DOI: 10.1056/ NEJMoa2001282.

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al.2004 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6

Susilo1 Adityo.2019 Coronavirus Disease 2019: riview of current literatures 2020-04-13415-1924-1-

World Health Organization. 2020. Pertimbangan langkah-langkah kesehatan masyarakat dan sosial di tempat kerja dalam konteks COVID-19. WHO

Pedoman Umum Menghadapi Pandemi Covid-19 Bagi Pemerintah Daerah 2020

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. 2020 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis.; published onlineMarch 9

Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI). 2020 Protokol Tatalaksana Covid-19. Edisi ke-1

Perhimpunan Dokter Paru Indonesia. 2020 Pneumonia COVID-19, Diagnosis & Penatalaksanaan di Indonesia

Bimantara D. E. 2020. Peran Vitamin C Dalam Pengobatan COVID-19 Majority Volume 9 Nomor 1 Fakultas Kedokteran, Universitas Lampung. Lampung

Published

2021-01-20

How to Cite

1.
Triputri N, Noni Novisari Soeroso. Charasteristics of COVID-19 Patients Treated At Santa Elisabeth Medan Hospital 2020. Sumat. Med. J. [Internet]. 2021Jan.20 [cited 2024Nov.20];4(1). Available from: https://talenta.usu.ac.id/smj/article/view/5958

Issue

Vol. 4 No. 1 (2021): Sumatera Medical Journal (SUMEJ)

Section

Research Article

Copyright (c) 2021 Sumatera Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Sumatera Medical Journal (SUMEJ) and Faculty of Medicine as well as TALENTA Publisher Universitas Sumatera Utara as publisher of the journal.

Copyright encompasses exclusive rights to reproduce and deliver the article in all form and media. The reproduction of any part of this journal, its storage in databases and its transmission by any form or media, will be allowed only with a written permission from Sumatera Medical Journal (SUMEJ).

The Copyright Transfer Form can be downloaded here.
The copyright form should be signed originally and sent to the Editorial Office in the form of original mail or scanned document.